Richards, Alexandra S; Sossen, Bianca; Emery, Jon C; Horton, Katherine C; Heinsohn, Torben; Frascella, Beatrice; Balzarini, Federica; Oradini-Alacreu, Aurea; Häcker, Brit; Odone, Anna; +6 more... McCreesh, Nicky; Grant, Alison D; Kranzer, Katharina; Cobelens, Frank; Esmail, Hanif; Houben, Rein MGJ; (2023) Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study. The Lancet Global health, 11 (5). e684-e692. ISSN 2214-109X DOI: https://doi.org/10.1016/S2214-109X(23)00082-7
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
BACKGROUND: Prevalence surveys show a substantial burden of subclinical (asymptomatic but infectious) tuberculosis, from which individuals can progress, regress, or even persist in a chronic disease state. We aimed to quantify these pathways across the spectrum of tuberculosis disease. METHODS: We created a deterministic framework of untreated tuberculosis disease with progression and regression between three states of pulmonary tuberculosis disease: minimal (non-infectious), subclinical (asymptomatic but infectious), and clinical (symptomatic and infectious). We obtained data from a previous systematic review of prospective and retrospective studies that followed and recorded the disease state of individuals with tuberculosis in a cohort without treatment. These data were considered in a Bayesian framework, enabling quantitative estimation of tuberculosis disease pathways with rates of transition between states and 95% uncertainty intervals (UIs). FINDINGS: We included 22 studies with data from 5942 individuals in our analysis. Our model showed that after 5 years, 40% (95% UI 31·3-48·0) of individuals with prevalent subclinical disease at baseline recover and 18% (13·3-24·0) die from tuberculosis, with 14% (9·9-19·2) still having infectious disease, and the remainder with minimal disease at risk of re-progression. Over 5 years, 50% (40·0-59·1) of individuals with subclinical disease at baseline never develop symptoms. For those with clinical disease at baseline, 46% (38·3-52·2) die and 20% (15·2-25·8) recover from tuberculosis, with the remainder being in or transitioning between the three disease states after 5 years. We estimated the 10-year mortality of people with untreated prevalent infectious tuberculosis to be 37% (30·5-45·4). INTERPRETATION: For people with subclinical tuberculosis, classic clinical disease is neither an inevitable nor an irreversible outcome. As such, reliance on symptom-based screening means a large proportion of people with infectious disease might never be detected. FUNDING: TB Modelling and Analysis Consortium and European Research Council.
Item Type | Article |
---|---|
Faculty and Department |
Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology & Dynamics (2023-) Faculty of Infectious and Tropical Diseases > Dept of Clinical Research |
Research Centre |
TB Centre ?? XZIM ?? TB Modelling Group Centre for the Mathematical Modelling of Infectious Diseases |
PubMed ID | 36966785 |
Elements ID | 201069 |
Official URL | http://dx.doi.org/10.1016/s2214-109x(23)00082-7 |
Download
Filename: Richards et al. - 2023 - Quantifying progression and regression across the .pdf
Licence: Creative Commons: Attribution 4.0
Download